Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder

Therapeutic Drug Monitoring

Volumn 35, Issue 3, 2013, Pages 279-282

  Geber, Christian ^a,b   Haji, Elnaz Ostad ^b   Schlicht, Konrad ^b   Hiemke, Christoph ^b   Tadic, André ^b  

^a Departments of Neurology   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cotrimoxazole; CYP2C19; Metabolism; Tremor; Venlafaxine

Indexed keywords

COTRIMOXAZOLE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESVENLAFAXINE; DULOXETINE; LITHIUM CARBONATE; N DEMETHYLASE; NORADRENALIN; O DEMETHYLASE; VENLAFAXINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLADDER INFECTION; CASE REPORT; CONSULTATION; DEMETHYLATION; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GENETIC DISORDER; GENOTYPE; HUMAN; INFECTION; LOW DRUG DOSE; MAJOR DEPRESSION; NAUSEA; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; SEROTONIN UPTAKE; SIDE EFFECT; TREMOR;

ANTI-INFECTIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; FEMALE; HUMANS; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREMOR; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84880066451     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31828816e0     Document Type: Article

References (16)

1. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57:503-509. (Pubitemid 30257265)
2. Fogelman SM, Schmider J, Venkatakrishnan K, et al. O-And N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999;20:480-490. (Pubitemid 29123875)
3. Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other idnetified metabolites of the antidepressant venlafaxine. Drug Dev Res. 1991;23:191-199.
4. Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006;31:493-502. (Pubitemid 44337299)
5. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.
6. Kohler D, Hartter S, Fuchs K, et al. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics. 1997;7:453-461. (Pubitemid 27517573)
7. Fukuda T, Nishida Y, Zhou Q, et al. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol. 2000;56:175-180. (Pubitemid 30341393)
8. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit. 2005;27:478-483. (Pubitemid 41098823)
9. McAlpine DE, Biernacka JM, Mrazek DA, et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit. 2011;33:14-20.
10. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004;60:329-336. (Pubitemid 39062319)
11. Tamminga WJ, Wemer J, Oosterhuis B, et al. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol. 2001;57:717-722. (Pubitemid 34031264)
12. Wen X, Wang JS, Backman JT, et al. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 2002;30:631-635. (Pubitemid 34579094)
13. Bua J, Marchetti F, Barbi E, et al. Tremors and chorea induced by trimethoprim-sulfamethoxazole in a child with Pneumocystis pneumonia. Pediatr Infect Dis J. 2005;24:934-935. (Pubitemid 41475937)
14. Patterson RG, Couchenour RL. Trimethoprim-sulfamethoxazole-induced tremor in an immunocompetent patients. Pharmacotherapy. 1999;19: 1456-1458.
15. Pfuhlmann B, Hiemke C, Unterecker S, et al. Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol. 2009; 29:392-394.
16. Espnes KA, Heimdal KO, Spigset O. A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. Ther Drug Monit. 2012;34:489-492.